NEW YORK, Jan 3 — One Genzyme business division has agreed to sell its cancer diagnostics intellectual property and licensing to another division, the company announced on Thursday.
Registering provides access to this and other free content.
Already have an account?Login Now.
In Science this week: global genetic diversity map, and more.
The Nuffield Council on Bioethics identifies ethical questions to explore surrounding genome editing.
In a blog post, Brigham and Women's Hospital's Robert Green discusses "predispositional personal genome sequencing."
Stat News reports that there's muted opposition to the Kuwaiti DNA database law.